In the new analysis presented at the ESMO Immuno-Oncology congress this week, Keytruda reduced the risk of death by 58% in patients with any KRAS mutation, and by 78% in those with a specific ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

The study, featured on the cover of the Journal of Thoracic Oncology, reveals a potential game-changer for patients battling ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy. Adding immunotherapy to a new type of ...